Ann: Change in substantial holding, page-121

I think the hypothetical question here is: if someone was offered 20 -30 dollars per share right now, would they take it?

that's 5-8 times the SP now. I believe most would say yes(personal opinion), despite what the board would suggest. That is a massive increase in someone's investment and not common in most instances.

I feel the board has an intrinsic value in their minds, and it's closer to the value of keytruda than it is magrolimab(forty seven).

my opinion: they've done the in depth research into how high a chance this will translate from pre clinical to humans. I reckon they believe based on the science that this is high. Their biggest risk is designing the trial, although I feel this may be easier than trying to prove something over standard of care, as to get a patient or doctor to try something over the well known treatment is quite difficult. I may be completely out of my depth with this assumption, and if so I hope someone can correct me.